Selinexor in Combination with Venetoclax and Azacitidine for Newly Diagnosed (ND) Unfit Acute Myeloid Leukemia (AML): A Multicenter, Open-Label Prospective Study

被引：1
|
作者：
Yang, Li [1 ]
Chen, Fangli [1 ]
Liang, Hong [2 ]
Bai, Yunsong [3 ]
Wu, Wenzhong [4 ]
Yan, Xiaojing [5 ]
Ren, Jinhai [6 ]
Li, Si [2 ]
Yu, Yang [2 ]
Tong, Laigen [4 ]
Pan, Deng [5 ]
Liu, Ligen [1 ]
机构：
[1] Shanghai Jiao Tong Univ, Tongren Hosp, Sch Med, Dept Hematol,Hongqiao Int Inst Med, Shanghai, Peoples R China
[2] Harbin Inst Hematol & Oncol, Dept Hematol & Oncol, Haerbin, Peoples R China
[3] Jilin Univ, China Japan Union Hosp, Dept Hematol, Changchun, Peoples R China
[4] Yixing Peoples Hosp, Yixing, Peoples R China
[5] China Med Univ, Hosp 1, Shenyang, Peoples R China
[6] Hebei Med Univ, Hosp 2, Dept Hematol, Shijiazhuang, Hebei, Peoples R China
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-184581
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] A Randomized Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy
    Short, Nicholas J.
    Sedarati, Farhad
    Zhao, Dan
    Tsukurov, Olga
    Friedlander, Sharon
    Faller, Douglas V.
    BLOOD, 2020, 136
  • [2] RESULTS OF A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF AZACITIDINE (AZA) VS CONVENTIONAL CARE REGIMENS (CCR) IN OLDER PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML)
    Dombret, H.
    Seymour, J. F.
    Butrym, A.
    Wierzbowska, A.
    Selleslag, D.
    Jang, J. H.
    Kumar, R.
    Cavenagh, J.
    Schuh, A.
    Candoni, A.
    Recher, C.
    Sandhu, I.
    Bernal, T.
    Al-Ali, H. K.
    Martinelli, G.
    Stone, R. M.
    Minden, M. D.
    McIntyre, H.
    Songer, S.
    Lucy, L.
    Beach, C.
    Doehner, H.
    HAEMATOLOGICA, 2014, 99 : 788 - 789
  • [3] Azacitidine and venetoclax with or without pevonedistat in patients with newly diagnosed acute myeloid leukemia
    Short, Nicholas J.
    Wierzbowska, Agnieszka
    Cluzeau, Thomas
    Laribi, Kamel
    Recher, Christian
    Czyz, Jaroslaw
    Ochrem, Bogdan
    Ades, Lionel
    Gallego-Hernanz, Maria Pilar
    Heiblig, Mael
    Audisio, Ernesta
    Zarzycka, Ewa
    Li, Shuli
    Ferenc, Nicholas
    Yeh, Tammie
    Faller, Douglas V.
    Sedarati, Farhad
    Papayannidis, Cristina
    LEUKEMIA & LYMPHOMA, 2025, 66 (03) : 458 - 468
  • [4] Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost-Utility Analysis
    Guinan, Kimberly
    Mathurin, Karine
    Au, Yunghan
    Schuh, Andre C.
    Bui, Cat N.
    Chai, Xinglei
    Lachaine, Jean
    CURRENT ONCOLOGY, 2022, 29 (10) : 7524 - 7536
  • [5] Safety and Efficacy of Cusatuzumab in Combination with Venetoclax and Azacitidine (CVA) in Patients with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Eligible for Intensive Chemotherapy; An Open-Label, Multicenter, Phase 1b Study
    Roboz, Gail J.
    Pabst, Thomas
    Aribi, Ahmed
    Brandwein, Joseph M.
    Dohner, Hartmut
    Fiedler, Walter
    Gandini, Domenica
    Geddes, Michelle
    Hou, Jing-Zhou
    Howes, Angela J.
    Hultberg, Anna
    Huselton, Eric
    Jacobs, Julie
    Kane, Colleen
    Lech-Maranda, Ewa
    Louwers, Marieke
    Nottage, Kerri
    Platzbecker, Uwe
    Rampal, Raajit
    Salman, Mariya
    Shah, Priya
    Stevens, Don
    Stuart, Monic
    Subklewe, Marion
    Sumbul, Anne
    Wang, Eunice S.
    Wierzbowska, Agnieszka
    Yao, Bin
    Yee, Karen
    Kantarjian, Hagop
    Borthakur, Gautam
    BLOOD, 2021, 138
  • [6] Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients
    Garciaz, Sylvain
    Hospital, Marie-Anne
    Alary, Anne-Sophie
    Saillard, Colombe
    Hicheri, Yosr
    Mohty, Bilal
    Rey, Jerome
    D'Incan, Evelyne
    Charbonnier, Aude
    Villetard, Ferdinand
    Maisano, Valerio
    Lombardi, Laura
    Ittel, Antoine
    Mozziconacci, Marie-Joelle
    Gelsi-Boyer, Veronique
    Vey, Norbert
    CANCERS, 2022, 14 (08)
  • [7] Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia
    Cherry, Evan M.
    Abbott, Diana
    Amaya, Maria
    McMahon, Christine
    Schwartz, Marc
    Rosser, Julie
    Sato, Audrey
    Schowinsky, Jeffrey
    Inguva, Anagha
    Minhajuddin, Mohd
    Pei, Shanshan
    Stevens, Brett
    Winters, Amanda
    Jordan, Craig T.
    Smith, Clayton
    Gutman, Jonathan A.
    Pollyea, Daniel A.
    BLOOD ADVANCES, 2021, 5 (24) : 5565 - 5573
  • [8] Phase 2 study of chidamide in combination with CAG and venetoclax-azacitidine in older patients with newly diagnosed acute myeloid leukemia
    Liu, Qingyang
    Yang, Jingjing
    Lv, Lei
    Zhang, Xiawei
    Li, Meng
    Xu, Lingmin
    Huang, Sai
    Jing, Yu
    Dou, Liping
    FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [9] A prospective study of all-trans retinoic acid plus venetoclax and azacitidine in newly diagnosed acute myeloid leukemia.
    Gu, Chengyuan
    Wang, Ruju
    Kang, Huizhu
    He, Xuefeng
    Chen, Jun
    Lin, Zhihong
    Liu, Yuejun
    Yang, Ting
    Wu, Depei
    Han, Yue
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] DIFFERENCES IN IMMUNE TRANSCRIPTOMIC PROFILE ARE ASSOCIATED WITH RESPONSE TO AZACITIDINE AND VENETOCLAX IN NEWLY DIAGNOSED UNFIT-FOR-CHEMOTHERAPY ACUTE MYELOID LEUKEMIA PATIENTS
    Zannoni, L.
    Forte, D.
    Sartor, C.
    Cristiano, G.
    Nanni, J.
    Parisi, S.
    Zingarelli, F.
    Bandini, L.
    Testoni, N.
    Ottaviani, E.
    Paolini, S.
    Papayannidis, C.
    Cavo, M.
    Rutella, S.
    Curti, A.
    HAEMATOLOGICA, 2024, 109 : 74 - 75
12345